Antibody Drug Conjugates Market (3rd Edition) - Estimated to be Worth Around $0.9 billion in 2015

Mar 14, 2016, 13:10 ET from Research and Markets

DUBLIN, March 14, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Antibody Drug Conjugates Market (3rd Edition)" report to their offering.

The ADC market is estimated to be worth around USD 0.9 billion in 2015. The market has a strong clinical pipeline of 53 molecules; nearly one-third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/ discovery stage; in our research, we came across over 60 such molecules.

About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.

With around 10 new ADC commercial launches over the coming decade, the report says the overall market will be worth USD 10 billion annually by 2025.

There has been a healthy growth in the number of pipeline molecules (both clinical and preclinical), suggesting a heavy focus of stakeholders in the industry. Majority of the drugs are being developed for oncological indications. In fact, several molecules are designed to target a large bandwidth of cancers, focussing on multiple indications; such molecules form 19% of the clinical pipeline.

The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Over 80 instances of funding (equity + debt) were traced during our research, with the total investment amounting to an encouraging sum of USD 1.9 billion over the last decade.

Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. KOL Analysis

6. Key Therapeutic Areas For ADCS

7. Upcoming ADC Drugs: Detailed Profiles And Market Forecast

8. Partnerships And Collaborations

9. Venture Capital Interest

10. Company Profiles

11. Case In Point: Contract Manufacturing In ADCs 

12. SWOT Analysis

13. Interview Transcripts

14. Conclusion

Companies Mentioned:

  • 5AM Ventures
  • AAIPharma Services Corp
  • ACES Pharma
  • ADC Therapeutics
  • AIDS Malignancy Consortium
  • ALMAC Group
  • AMRI Global
  • ARCH Venture Partners
  • AbGenomics
  • (350+ More)

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets